Skip to content

ELITE PHARMACEUTICALS INC /NV/

ELTP

CIK 0001053369

← back to feed
Revenue (TTM)
$122.49M
+48.4% YoY Q3 Feb 2026
Net Income (TTM)
$15.52M
−121.5% YoY Q3 Feb 2026
EPS Diluted (TTM)
$0.00
−100.0% YoY Q3 Feb 2026
Gross Margin
49.3%
Q3 Feb 2026
Operating Margin
32.7%
Q3 Feb 2026
Net Margin
12.7%
Q3 Feb 2026
Free Cash Flow (TTM)
$13.03M
Q3 Feb 2026
Cash
$7.11M
Q3 Feb 2026
Total Debt
$2.1M
Q3 Feb 2026
Shares Outstanding
1.08B sh
Q3 Feb 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings